DrugPatentWatch Database Preview

Details for Patent: 10,076,494

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,076,494 protect, and when does it expire?

Patent 10,076,494 protects ESOMEPRAZOLE MAGNESIUM and OMEPRAZOLE and is included in two NDAs.

This patent has three patent family members in three countries.

Summary for Patent: 10,076,494

Title:	Stable orally disintegrating pharmaceutical compositions
Abstract:	Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.
Inventor(s):	Pevzner; Victor (Hadera, IL), Moses-Heller; Sheera (Atlit, IL)
Assignee:	DEXCEL PHARMA TECHNOLOGIES LTD. (Or-Akiva, IL)
Application Number:	15/372,917
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent 10,076,494

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dexcel Pharma	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	214278-001	Oct 20, 2020		OTC	Yes	Yes			Y
Dexcel Pharma	OMEPRAZOLE	omeprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	209400-001	Jul 5, 2017		OTC	Yes	No			Y

International Family Members for US Patent 10,076,494

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017285390
European Patent Office	3471708
World Intellectual Property Organization (WIPO)	2017216789